Colon cancer can affect blood work in several ways, though no single routine blood test reliably diagnoses it. The changes that show up depend on the stage of the cancer, where it has spread, and how your body is responding to the disease. Some of these changes appear on standard blood panels your doctor might order for any reason, while others require cancer-specific tests.
Anemia Is Often the First Clue
The most common way colon cancer shows up in routine blood work is through a low red blood cell count, specifically iron deficiency anemia. Tumors in the colon can bleed slowly into the intestine, often in amounts too small to notice in your stool. Over weeks and months, this gradual blood loss depletes your iron stores, which eventually drags down your hemoglobin levels.
This finding is taken seriously. British gastroenterology guidelines recommend that men and postmenopausal women with newly diagnosed iron deficiency anemia should generally receive both an upper and lower endoscopy as first-line investigations. In the UK, a hemoglobin below 110 g/L in men or below 100 g/L in non-menstruating women with iron deficiency triggers a fast-track referral for suspected cancer. Age over 50 strengthens the case for investigation, since age is a strong predictor of malignancy risk when iron deficiency anemia is present. Even in younger men, confirmed iron deficiency anemia is uncommon enough that it warrants the same workup as in older patients.
If your routine blood work comes back showing low iron and low hemoglobin without an obvious explanation (like heavy menstrual periods or a known bleeding condition), your doctor will likely want to look at your colon.
What a Standard Blood Panel Can Reveal
Beyond anemia, a comprehensive metabolic panel can pick up other signals. Liver enzymes may become elevated when colon cancer spreads to the liver, which is one of the most common sites for metastasis. The American Cancer Society notes that liver function blood tests are part of the diagnostic workup for colorectal cancer for exactly this reason. Elevated liver enzymes alone don’t point to cancer specifically, but when combined with other findings, they prompt further imaging.
Albumin, a protein measured on standard blood panels, also carries important information. Cancer patients frequently have low albumin levels, and research in colorectal cancer has shown that each 0.5 g/dL drop in serum albumin is associated with roughly a 25% increase in the risk of death. Patients with metastatic disease tend to have lower albumin than those whose cancer hasn’t spread. Interestingly, this drop isn’t simply because cancer patients eat less. The current understanding is that low albumin in cancer reflects a systemic inflammatory response to the tumor rather than poor nutrition alone. Larger tumors tend to drive albumin levels down more than smaller ones, regardless of the specific stage.
A Taiwanese study of nearly 3,850 colon cancer patients found that low albumin predicted higher postoperative mortality for both early-stage and regionally advanced cancers, with the effect persisting up to five years after surgery.
The CEA Tumor Marker
Carcinoembryonic antigen, or CEA, is the blood marker most closely associated with colorectal cancer. The normal range is 0 to 2.5 ng/mL, though smokers can have levels up to 5 ng/mL without it being considered abnormal.
About 70% of colorectal cancer patients have elevated CEA at diagnosis, and the test has a reported sensitivity of roughly 77% with a specificity around 84%. Those numbers mean CEA catches most cases but misses some, and it occasionally flags people who don’t have cancer. A high CEA alone cannot diagnose cancer. It’s most useful for monitoring after treatment rather than for initial screening. Once cancer has been treated, rising CEA levels can signal a recurrence, though the test catches only about 33% of recurrences overall. Patients who had high CEA before surgery are more likely to show elevated levels again if the cancer returns (about 59%) compared to those whose initial CEA was normal (about 23%).
Blood-Based Screening Tests
A newer category of blood tests looks for fragments of tumor DNA circulating in the bloodstream. One such test received FDA authorization in 2024. In a clinical trial of over 27,000 participants, this type of blood test detected colorectal cancer with 79.2% sensitivity and 91.5% specificity, using colonoscopy results as the benchmark. That means it correctly identified about 4 out of 5 cancers and correctly cleared about 9 out of 10 people without advanced disease.
There’s an important limitation: these tests are much better at finding cancer that already exists than catching precancerous growths. The sensitivity for advanced precancerous lesions was only 12.5%, meaning the test missed the vast majority of polyps that haven’t yet turned into cancer. A colonoscopy remains far superior for catching and removing these growths before they become dangerous. Medicare covers blood-based screening tests once every three years for beneficiaries, provided the test meets minimum performance thresholds of 74% sensitivity and 90% specificity for colorectal cancer detection.
What Blood Work Cannot Do
No routine blood test can definitively diagnose colon cancer on its own. Anemia, abnormal liver enzymes, low albumin, and elevated CEA all raise suspicion, but each of these findings has many possible causes unrelated to cancer. Anemia can come from dietary deficiency. Liver enzymes rise with medications, alcohol use, or fatty liver disease. Albumin drops with liver disease, kidney problems, or any significant inflammation. CEA can be mildly elevated in smokers, people with inflammatory bowel disease, or those with other non-cancerous conditions.
What blood work does well is contribute to the overall picture. When several markers are off at once, or when a specific pattern like unexplained iron deficiency anemia appears in a person over 50, those results push doctors toward the imaging and procedures that can actually confirm or rule out cancer. A colonoscopy with biopsy remains the definitive way to diagnose colorectal cancer. Blood tests play a supporting role in getting you to that point and in tracking the disease after diagnosis.